- Data Expand Support for Development of Diagnostic to Identify Patients With Biomarkers of Anti-Progestin and Anti-Estrogen Activity -
- Bolster Findings Presented at ASCO and ECC 2013 -
Poster Session 6 Saturday, December 14; 7:30 - 9:00 a.m. CT Abstract #1282 Poster #P6-05-13FLEMINGTON, N.J., Dec. 14, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that data from a biomarker study supporting its lead compound onapristone will be presented at a poster session at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) annual meeting, being held December 10-14, 2013 in San Antonio, Texas. The symposium is hosted by the American Association for Cancer Research, The Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine. Findings from the study "Tumor and Cellular Distribution of Activated Forms of ERα and PR in Breast Cancers" (Abstract #1282) will be presented during Poster Session 6 on Tumor Cell and Molecular Biology: Biomarkers on Saturday, December 14 from 7:30 – 9:00 a.m. CT in Exhibit Hall C of the Henry B. Gonzalez Convention Center. Data analysis from primary breast cancers further support the development of a diagnostic test to identify patient tumors with activated progesterone receptor (APR) and activated estrogen receptor (AER) as potential biomarkers of anti-progestin and anti-estrogen activity, respectively. Onapristone is an oral, anti-progestin hormone blocker that has been shown to have anti-tumor activity in breast cancer. Onapristone appears to have a unique ability to block the APR, which is believed to be a mechanism that may inhibit the growth of breast, endometrial and other tumors. APR has the potential to function as a biomarker of anti-progestin activity.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts